RT Journal Article
SR Electronic
T1 Reduced magnitude and durability of humoral immune responses by COVID-19 mRNA vaccines among older adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.06.21263149
DO 10.1101/2021.09.06.21263149
A1 Brockman, Mark A.
A1 Mwimanzi, Francis
A1 Lapointe, Hope R.
A1 Sang, Yurou
A1 Agafitei, Olga
A1 Cheung, Peter
A1 Ennis, Siobhan
A1 Ng, Kurtis
A1 Basra, Simran
A1 Lim, Li Yi
A1 Yaseen, Fatima
A1 Young, Landon
A1 Umviligihozo, Gisele
A1 Omondi, F. Harrison
A1 Kalikawe, Rebecca
A1 Burns, Laura
A1 Brumme, Chanson J.
A1 Leung, Victor
A1 Montaner, Julio S.G.
A1 Holmes, Daniel
A1 DeMarco, Mari
A1 Simons, Janet
A1 Pantophlet, Ralph
A1 Niikura, Masahiro
A1 Romney, Marc G.
A1 Brumme, Zabrina L.
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.06.21263149.abstract
AB Background mRNA vaccines reduce COVID-19 incidence and severity, but the durability of vaccine-induced immune responses, particularly among the elderly, remains incompletely characterized.Methods Anti-spike RBD antibody titers, ACE2 competition and virus neutralizing activities were longitudinally assessed in 151 healthcare workers and older adults (overall aged 24-98 years) up to three months after vaccination.Results Older adults exhibited lower antibody responses after one and two vaccine doses for all measures. In multivariable analyses correcting for sociodemographic, chronic health and vaccine-related variables, age remained independently associated with all response outcomes. The number of chronic health conditions was additionally associated with lower binding antibody responses after two doses, and male sex with lower ACE2 competition activity after one dose. Responses waned universally at three months after the second dose, but binding antibodies, ACE2 competition and neutralizing activities remained significantly lower with age. Older adults also displayed reduced ability to block ACE2 binding by the Delta variant.Conclusions The humoral immune response to COVID-19 mRNA vaccines is significantly weaker with age, and universally wanes over time. This will likely reduce antibody-mediated protection against SARS-CoV-2 and the Delta variant as the pandemic progresses. Older adults may benefit from additional immunizations as a priority.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Public Health Agency of Canada through a COVID-19 Immunology Task Force COVID-19 "Hot Spots" Award (2021-HQ-000120 to MAB, ZLB, MGR) and the Canada Foundation for Innovation through Exceptional Opportunities Fund COVID-19 awards (to MAB, MN, MD, RP, ZLB) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI134229 to RP). GU and FHO are supported by Ph.D. fellowships from the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant number DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africas Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant number 107752 Z 15 Z) and the UK government. The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. LYL was supported by an SFU Undergraduate Research Award. ZLB holds a Scholar Award from the Michael Smith Foundation for Health Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all participants or their authorized substitute decision makers. This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards (protocol H20-03906).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs per funder requirements, data will be deposited into a national database hosted by the Canadian COVID-19 Immunity Task Force (CITF) by the study end date (Spring 2022). Prior to then, data are available to interested researchers upon reasonable request to the corresponding authors.